v3.25.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
$ / shares in Thousands, $ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Unrestricted cash and cash equivalents $ 350,390 $ 375,416
Restricted cash and cash equivalents 111,059 124,220
Loans, interest and fees receivable, at fair value 2,668,503 2,630,274
Allowance for credit losses 4,800 4,900
Deferred revenue 20,100 19,800
Notes payable, at face value $ 2,174,632 $ 2,199,448
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 15,097,243 14,904,192
Common stock, outstanding (in shares) 15,097,243 14,904,192
Series A Preferred Stock [Member]    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 400,000 400,000
Preferred stock, shares outstanding (in shares) 400,000 400,000
Preferred stock, liquidation preference $ 40,000 $ 40,000
Series B Preferred Stock [Member]    
Preferred stock, no par value (in dollars per share) $ 0 $ 0
Preferred stock, shares issued (in shares) 3,314,840 3,301,179
Preferred stock, shares outstanding (in shares) 3,314,840 3,301,179
Preferred stock, liquidation preference $ 82,900 $ 82,500
Variable Interest Entity, Primary Beneficiary [Member]    
Unrestricted cash and cash equivalents 164,300 140,200
Restricted cash and cash equivalents 86,900 98,800
Loans, interest and fees receivable, at fair value 2,622,400 2,542,900
Notes payable, at face value $ 2,137,600 $ 2,128,000